Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension
- 16 April 2021
- journal article
- research article
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 22 (4), 330-340
- https://doi.org/10.1631/jzus.b2000730
Abstract
Epidemiological evidence suggests that patients with hypertension infected with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) are at increased risk of acute lung injury. However, it is still not clear whether this increased risk is related to the usage of renin-angiotensin system (RAS) blockers. We collected medical records of coronavirus disease 2019 (COVID-19) patients from the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China), and evaluated the potential impact of an angiotensin II receptor blocker (ARB) on the clinical outcomes of COVID-19 patients with hypertension. A total of 30 hypertensive COVID-19 patients were enrolled, of which 17 were classified as non-ARB group and the remaining 13 as ARB group based on the antihypertensive therapies they received. Compared with the non-ARB group, patients in the ARB group had a lower proportion of severe cases and intensive care unit (ICU) admission as well as shortened length of hospital stay, and manifested favorable results in most of the laboratory testing. Viral loads in the ARB group were lower than those in the non-ARB group throughout the disease course. No significant difference in the time of seroconversion or antibody levels was observed between the two groups. The median levels of soluble angiotensin-converting enzyme 2 (sACE2) in serum and urine samples were similar in both groups, and there were no significant correlations between serum sACE2 and biomarkers of disease severity. Transcriptional analysis showed 125 differentially expressed genes which mainly were enriched in oxygen transport, bicarbonate transport, and blood coagulation. Our results suggest that ARB usage is not associated with aggravation of COVID-19. These findings support the maintenance of ARB treatment in hypertensive patients diagnosed with COVID-19.Keywords
Funding Information
- National Natural Science Foundation of China (82072377, 81971919)
- the Department of Education of Zhejiang Province (Y202043382)
This publication has 30 references indexed in Scilit:
- Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19Circulation Research, 2020
- Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19Cardiovascular Research, 2020
- Structural basis of receptor recognition by SARS-CoV-2Nature, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet Respiratory Medicine, 2020
- Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertensionEmerging Microbes & Infections, 2020
- Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virusGenome Biology, 2017
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005